<- Go Home
RUA Life Sciences plc
RUA Life Sciences plc, together with its subsidiaries, engages in the provision of polymers, services, and products to the medical device industry in Europe, the United States, and internationally. The company operates through Biomaterials, Contract Manufacture, Vascular, and Structural Heart segments. The Biomaterials segment operates as depository of the Intellectual Property and licensing rights to a range of biostable and implantable polymers, including Elast-Eon and ECSil. The Contract Manufacture segment provides sub-contract manufacturing, assembly, packing and services to the medical device. The Vascular segment develops and commercializes bore polymer sealed grafts and soft tissue patches. The Structural Heart segment develops tri leaflet polymeric heart valves. The company was formerly known as AorTech International plc and changed its name to RUA Life Sciences plc in June 2020. RUA Life Sciences plc was incorporated in 1996 and is headquartered in Irvine, the United Kingdom.
Market Cap
GBP 7.6M
Volume
353.1K
Cash and Equivalents
GBP 3.6M
EBITDA
GBP 401.0K
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
GBP 3.2M
Profit Margin
77.12%
52 Week High
GBP 0.14
52 Week Low
GBP 0.10
Dividend
N/A
Price / Book Value
1.04
Price / Earnings
7.7K
Price / Tangible Book Value
1.15
Enterprise Value
GBP 5.2M
Enterprise Value / EBITDA
12.86
Operating Income
-GBP 20.0K
Return on Equity
0.01%
Return on Assets
-0.14
Cash and Short Term Investments
GBP 3.6M
Debt
GBP 1.0M
Equity
GBP 7.4M
Revenue
GBP 4.1M
Unlevered FCF
-GBP 52.5K
Sector
Health Care Equipment and Supplies
Category
N/A
Hedge Funds that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Professional Funds that own this company (and many other perks).
Upgrade to Yellowbrick PremiumYellowbrick Portfolios that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Yellowbrick portfolios that own this company (and many other perks).
Upgrade to Yellowbrick Premium